Us Healthcare

As US lawmakers push to reshore pharmaceutical production, a crucial question remains—are they focusing on the right cost drivers in healthcare?

US drug shortages as much a threat as an opportunity for Indian pharma

Falling margins even the extra demand created by the shortage may not bring cheer to them. But rival China may step into the breach

Woman charged $40 for crying during doctor’s appointment, Twitter united in outrage

A US woman says her younger sister was charged $40 for crying during a doctor’s visitor.

Wall Street could well correct by up to 10% in near term: Geoff Lewis

On the back of strong macroeconomic data, a correction is overdue but relatively mild. It would not extend to 15-20 percent. The maximum downside is around 10 percent,” he said.

US health care system frustrating: Seema Verma

America's health care system is frustrating and is becoming more and more expensive, putting paid to people's hopes of getting the medical services they need, Indian-American Seema Verma, who has been nominated by US President Donald Trump for a key health position, has said.

Pharma cos await Trump decision on FDA Commissioner: Steve Usdin

During his campaign, US president Donald Trump vowed to ease the burden of the healthcare industry in US by reducing taxes and government regulations. Two important decisions expected from the Trump administration is appointment of Food and Drug Administration (FDA) commissioner and drug price control.

Johnson & Johnson to buy Actelion for $30 bn, spin off R&D unit

US healthcare giant Johnson & Johnson will acquire Swiss biotech company Actelion in a USD 30 billion all-cash deal that includes spinning off Actelion's research and development pipeline, the companies said on Thursday.

2017's 'outrageous' calls: China shares to double; UK to Bremain

Doubling of bitcoin prices, halving of US healthcare stock prices, a brutal sell-off in copper prices and Britain choosing to remain in the European Union are some forecasts by Copenhagen-based Saxo Bank‘s in its report ‘Outrageous predictions for 2017‘.

Sun Pharma hit; US cancer drug supply contact may end

Shares in Sun Pharmaceutical Industries fall 1.6 percent on worries the drug maker will soon see an end to its temporary arrangement to supply a cancer drug in the United States.